Monte Rosa Therapeutic Investor Relations Material
Latest events
Q4 2024
Monte Rosa Therapeutic
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Monte Rosa Therapeutic Inc
Access all reports
Monte Rosa Therapeutics Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs). These small molecules are designed to selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation processes. The company targets a range of therapeutic areas, including oncology, autoimmune, and inflammatory diseases. Monte Rosa utilizes its proprietary QuEEN platform, which integrates proteomics, structural biology, AI, and machine learning, to rapidly identify and develop highly selective protein degraders. The company operates out of Boston, Massachusetts, with additional research facilities in Basel, Switzerland. Its shares trade on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
GLUE
Country
🇺🇸 United States